We present a rare experience with a myeloma patient who had a late relapse as isolated extramedullary plasmacytoma of the thyroid gland after a second allogeneic transplantation. We give PET/CT scan findings at diagnosis and during follow up of the disease after subsequent management. The possible pathogenesis of the late extramedullary relapse of myeloma after allogeneic stem-cell transplantation and management options are discussed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1399-0012.2009.01069.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Adjuvant Immunotherapy After Resected Melanoma: Survival Outcomes, Prognostic Factors and Patterns of Relapse.
Cancers (Basel)
January 2025
Department of Medical Oncology, Hospital de la Santa Creu I Sant Pau, 08025 Barcelona, Spain.
Background: Anti-PD-1-based immunotherapy has improved outcomes in stage IIB to IV resected melanoma patients in clinical trials. However, little is known about real-world outcomes, prognostic factors and patterns of relapse.
Methods: This is a retrospective multicenter observational study including patients with resected melanoma treated with subsequent anti-PD-1-based adjuvant immunotherapy.
A comparison of the clinicopathological features and genetic alterations in stage II/III gastric cancer with no recurrence, early recurrence and late recurrence after curative surgery.
J Chin Med Assoc
November 2024
School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Background: Few studies have explored the genetic changes and clinicopathological features of stage II/III gastric cancer (GC) patients with no tumor recurrence, early recurrence, or late recurrence after curative surgery.
Methods: In this study, 376 patients who underwent curative surgery for stage II/III GC were analyzed. The clinical and genetic features of patients with no recurrence, early recurrence (<2 years), and late recurrence (≥2 years) were compared.
Ovarian squamous cell carcinoma: clinicopathological features, prognosis and immunotherapy outcomes.
J Gynecol Oncol
December 2025
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, National Clinical Research Center for Obstetric & Gynecologic Diseases, Beijing, China.
Objective: To explore the characteristics and survival outcomes of ovarian squamous cell carcinoma (SCC) and the treatment effectiveness of immune checkpoint inhibitors (ICIs).
Methods: Patients diagnosed with ovarian SCC at Peking Union Medical College Hospital between January 2000 and September 2023 were included. Overall survival (OS) and progression-free survival (PFS) were analyzed using the Kaplan-Meier method.
Late corneal guttae recurrence in bilateral penetrating keratoplasty grafts.
Eur J Ophthalmol
January 2025
Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, Florida, USA.
Background: To describe a case of guttae recurrence in bilateral corneal grafts in a patient with a known diagnosis of Fuchs endothelial dystrophy, more than three decades following penetrating keratoplasty.
Methods: Case Report.
Results: A 79-year-old White woman presented with declining vision, right eye worse than the left.
Late Ultra-High-Risk Recurrence of Gestational Trophoblastic Neoplasia Seven Years Posttreatment.
Cureus
December 2024
Obstetrics and Gynecology, University of Medicine and Pharmacy at Ho Chi Minh, Ho Chi Minh, VNM.
Gestational trophoblastic neoplasia (GTN) comprises a category of malignant or potentially malignant tumors that arise from gestational trophoblasts. Almost all cases of GTN experience a recurrence within the first year following treatment, although recurrences become rare after five years. Recurrent GTN tends to have a poor prognosis, primarily due to challenges in management, a high rate of relapse, and a low five-year survival rate.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!